Nancy E. Denyes
2023
In 2023, Nancy E. Denyes earned a total compensation of $651.3K as General Counsel at aTYR PHARMA, a 24% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $111,058 |
|---|---|
| Option Awards | $133,084 |
| Salary | $396,635 |
| Other | $10,506 |
| Total | $651,283 |
Denyes received $396.6K in salary, accounting for 61% of the total pay in 2023.
Denyes also received $111.1K in non-equity incentive plan, $133.1K in option awards and $10.5K in other compensation.
Rankings
In 2023, Nancy E. Denyes' compensation ranked 1,723rd out of 3,006 executives tracked by ExecPay. In other words, Denyes earned more than 42.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,723 out of 3,006 | 43rd |
Division Manufacturing | 1,008 out of 1,650 | 39th |
Major group Chemicals And Allied Products | 639 out of 918 | 30th |
Industry group Drugs | 623 out of 881 | 29th |
Industry Biological Products, Except Diagnostic Substances | 165 out of 213 | 23rd |
Source: SEC filing on April 5, 2024.
Denyes' colleagues
We found two more compensation records of executives who worked with Nancy E. Denyes at aTYR PHARMA in 2023.